Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion type Assertion NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_head.
- NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion description "[Patients with mCRC refractory to standard therapies were a subset of patients from a phase III trial of panitumumab plus best supportive care (BSC; n = 58) versus BSC alone (n = 34) who were selected on the basis of availability of tumor samples adequate for FISH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_provenance.
- NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion evidence source_evidence_literature NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_provenance.
- NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion SIO_000772 17664472 NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_provenance.
- NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion wasDerivedFrom befree-20140225 NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_provenance.
- NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_assertion wasGeneratedBy ECO_0000203 NP616121.RADu62yaBNpXqnCwbe6tL-AWPngzzws1FPnHG-Alq2wco130_provenance.